Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ovarian cancer vaccine - MabVax/MSKCC

Next Previous
Drug Profile

Ovarian cancer vaccine - MabVax/MSKCC

Alternative Names: MV-Ovar; NSC-748933; Polyvalent vaccine-KLH conjugate - MabVax

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Gynecologic Oncology Group; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA)
  • Class Cancer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 10 Jun 2015 Phase-II development in Ovarian cancer is ongoing in the US
  • 08 Jul 2014 MabVax Therapeutics merged with a wholly-owned subsidiary of Telik
  • 28 May 2013 Memorial Sloan-Kettering Cancer Center completes enrolment in its phase II trial for Ovarian cancer in USA (NCT00857545)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top